Table 1.

Patient characteristics

N (%)
Total cases (≥2 years)4166 (100)
Age (years)
    2 to 5836 (20.1)
    6 to 121681 (40.4)
    >121649 (39.6)
Gender
    male2562 (61.5)
    female1604 (38.5)
Race
    white2539 (60.9)
    African American786 (18.9)
    Hispanic577 (13.9)
    other257 (6.2)
Primary diagnosis
    obstructive uropathy837 (20.1)
    focal segmental glomerulosclerosis478 (11.5)
    renal dysplasia529 (12.7)
    reflux nephropathy389 (9.3)
    other1833 (44.0)
Anemia
    hematocrit ≥33%2589 (62.1)
    hematocrit <33%1577 (37.9)
CKD stage
    stage II828 (19.9)
    stage III2162 (51.9)
    stage IV1176 (28.2)
CRI registry year
    before 20002795 (67.1)
    2000 and after1371 (32.9)
Erythropoietin use
    yes557 (13.4)
    no3606 (86.6)
Growth hormone use
    yes281 (6.7)
    no3878 (93.1)
Calcium (corrected)
    low214 (5.1)
    normal2728 (65.5)
    high632 (15.2)
Phosphorus
    normal2654 (63.7)
    elevated1177 (28.3)
Parathyroid hormone
    <2× upper limit1477 (35.5)
    >2× upper limit853 (20.5)
    unknown1836 (44.1)
Iron supplementation
    yes997 (23.9)
    no3157 (75.8)
Anti-hypertensive medication use
    yes1928 (46.3)
    no2230 (53.5)
Albumin
    ≤4.0 g/dl1954 (46.9)
    >4.0 g/dl1674 (40.2)
Hypertension
    yes1954 (46.9)
    no2154 (51.7)
  • Percents may not total 100% because of missing values.